Why Odyssey Therapeutics, Inc.’s (ODTX) Stock Is Up 5.90%
As of Wednesday, September 02, Odyssey Therapeutics, Inc.’s ODTX share price has surged by 5.90%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptor–associated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5. The company was incorporated in 2021 and is headquartered in Boston, Massachusetts.
Commentary & Analysis
Why Odyssey Therapeutics, Inc.’s (ODTX) Stock Is Up 5.73%
As of Tuesday, August 25, Odyssey Therapeutics, Inc.’s ODTX share price has surged by 5.73%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Odyssey Therapeutics, Inc.’s (ODTX) Stock Is Up 7.47%
As of Wednesday, August 19, Odyssey Therapeutics, Inc.’s ODTX share price has surged by 7.47%, which has investors questioning if this is right time to sell.Michael Rose
Why Odyssey Therapeutics, Inc.’s (ODTX) Stock Is Up 5.01%
As of Wednesday, August 12, Odyssey Therapeutics, Inc.’s ODTX share price has surged by 5.01%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Odyssey Therapeutics, Inc.’s (ODTX) Stock Is Up 5.08%
As of Monday, July 27, Odyssey Therapeutics, Inc.’s ODTX share price has surged by 5.08%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | ODTX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,275.6 | $288.9 | 48% |
|
| Shares Out (Mil) | 30.3 | 54.0 | 37% |
|
| Institutional Ownership | 94.2% | 93.1% | 64% |
|
| Float (Mil) | 23.7 | 41.4 | 31% |
|
| Beta | na | 0.94 | na |
|
| Avg Daily Volume (000s) | 173 | 480 | 44% |
|
| Price Change (52-week) |
na | 59.9% | na |
|
| Growth | ODTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.9% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 3 | |
| Current EPS | ($0.930) | ($4.255) | ($4.360) | |
| Month Ago EPS | ($0.890) | ($4.218) | ($3.876) | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | ($0.827) | ($3.560) | ($3.825) | |
| Year/Year Chg | (46.6%) | (91.5%) | (90.6%) | |
| Financials | ODTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($160) | ($43) | 8% |
|
| EPS (TTM) | ($14.051) | ($1.500) | 3% |
|
| Operating Cash Flow (TTM) (Mil) | ($132) | ($31) | 5% |
|
| Net Cash Flow (TTM) (Mil) | $145 | $2 | 81% |
|
| Long-Term Debt (Q1) (Mil) | $19 | $4 | 32% |
|
| Enterprise Value (Q1) (Mil) | $654 | $190 | 36% |
|
| Valuation | ODTX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.02 | 2.84 | 65% |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | ODTX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (41.5%) | (47.7%) | 13% |
|
| ROE | (201.9%) | (55.0%) | 4% |
|
| Liabilities to Assets | 12.9% | 29.6% | 8% |
|
| F-Score | 2 | 3 | na |
|
Odyssey Therapeutics, Inc. did not pass any screens on 9/2/2026.
